ZNF528

Summary

ZNF528 (zinc finger protein 528, HGNC:29384) is a protein-coding gene on chromosome 19q13.41, encoding Zinc finger protein 528 (Q3MIS6). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 84436 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 129 total
• MANE Select transcript: NM_032423

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29384
Approved symbol	ZNF528
Name	zinc finger protein 528
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1827
Ensembl gene	ENSG00000167555
Ensembl biotype	protein_coding
OMIM	615580
Entrez	84436

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000360465, ENST00000391787, ENST00000391788, ENST00000436397, ENST00000448954, ENST00000479718, ENST00000493272, ENST00000494167, ENST00000531472, ENST00000594530, ENST00000598192, ENST00000598479, ENST00000862203, ENST00000862204, ENST00000940144

RefSeq mRNA: 1 — MANE Select: NM_032423 NM_032423

CCDS: CCDS33091

Canonical transcript exons

ENST00000360465 — 7 exons

Exon	Start	End
ENSE00001114287	52398367	52398619
ENSE00001639591	52401685	52401753
ENSE00001671477	52415124	52418401
ENSE00001798420	52397849	52397904
ENSE00002460720	52406515	52406643
ENSE00003494309	52405907	52406033
ENSE00003647276	52401947	52402028

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 99.34.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.6475 / max 143.5361, expressed in 1511 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177303	6.6475	1511

Top tissues by expression

262 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	99.34	gold quality
sural nerve	UBERON:0015488	96.01	gold quality
calcaneal tendon	UBERON:0003701	93.89	gold quality
tendon	UBERON:0000043	91.15	gold quality
tendon of biceps brachii	UBERON:0008188	90.05	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.91	gold quality
right uterine tube	UBERON:0001302	89.31	gold quality
cortical plate	UBERON:0005343	89.14	gold quality
ganglionic eminence	UBERON:0004023	89.00	gold quality
cerebellar hemisphere	UBERON:0002245	88.79	gold quality
cerebellar cortex	UBERON:0002129	88.54	gold quality
right lobe of thyroid gland	UBERON:0001119	88.19	gold quality
left lobe of thyroid gland	UBERON:0001120	87.86	gold quality
thyroid gland	UBERON:0002046	87.36	gold quality
left ovary	UBERON:0002119	87.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.32	gold quality
adrenal tissue	UBERON:0018303	87.10	gold quality
tibial nerve	UBERON:0001323	86.09	gold quality
right ovary	UBERON:0002118	86.05	gold quality
ventricular zone	UBERON:0003053	85.99	gold quality
cerebellum	UBERON:0002037	85.66	gold quality
apex of heart	UBERON:0002098	85.63	gold quality
colonic epithelium	UBERON:0000397	85.62	gold quality
minor salivary gland	UBERON:0001830	85.38	gold quality
right adrenal gland	UBERON:0001233	85.11	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.95	gold quality
ovary	UBERON:0000992	84.95	gold quality
body of uterus	UBERON:0009853	84.85	gold quality
adenohypophysis	UBERON:0002196	84.84	gold quality
right adrenal gland cortex	UBERON:0035827	84.80	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-6	yes	68.13
E-ANND-3	yes	5.74
E-MTAB-6386	no	460.43

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA1597.1	ZNF528	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:25690854

miRNA regulators (miRDB)

78 targeting ZNF528, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-891B	99.59	69.81	1083
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-7106-5P	99.53	67.47	3574

Literature-anchored findings (GeneRIF, showing 1)

• Exome Sequencing Reveals a Phenotype Modifying Variant in ZNF528 in Primary Osteoporosis With a COL1A2 Deletion. (PMID:32722848)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631)

Protein

Protein identifiers

Zinc finger protein 528 — Q3MIS6 (reviewed: Q3MIS6)

All UniProt accessions (8): A0A1D5RMT7, C9JLS3, C9K0H2, Q3MIS6, F8WAL3, J3KQN0, M0QXZ2, M0QZG9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q3MIS6-1	1	yes
Q3MIS6-2	2

RefSeq proteins (1): NP_115799* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050752	C2H2-ZF_domain	Family

Pfam: PF00096, PF01352

UniProt features (20 total): zinc finger region 15, chain 1, domain 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3MIS6-F1	71.22	0.14

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 45 (showing top): MODULE_205, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, CTIP_DN.V1_UP, KRAS.300_UP.V1_UP, KRAS.600_UP.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, TRIP13_TARGET_GENES, ZNF512_TARGET_GENES, ZNF528_TARGET_GENES, MIR5696, MIR4729, MIR1827, MIR519E_5P

GO Biological Process (4): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of biosynthetic process (GO:0009891), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of DNA-templated transcription	1
regulation of DNA-templated transcription	1
biosynthetic process	1
regulation of biosynthetic process	1
positive regulation of metabolic process	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

288 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF528	GPR20	Q99678	424
ZNF528	CCL25	O15444	405
ZNF528	CXCL17	Q6UXB2	364
ZNF528	EMC9	Q9Y3B6	357
ZNF528	CCL14	Q16627	353
ZNF528	SYDE2	Q5VT97	321
ZNF528	SYCP2L	Q5T4T6	311
ZNF528	ZZEF1	O43149	291
ZNF528	RALGPS1	Q5JS13	280
ZNF528	RUSC1	Q9BVN2	280
ZNF528	PTOV1	Q86YD1	277
ZNF528	TMEM51	Q9NW97	275
ZNF528	URGCP	Q8TCY9	270
ZNF528	TCERG1L	Q5VWI1	267
ZNF528	RCBTB1	Q8NDN9	257

IntAct

2 interactions, top by confidence:

A	B	Type	Score
DSCR9	ZNF528	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): ZNF528 (Affinity Capture-RNA), ZNF528 (Affinity Capture-MS), ZNF528 (Two-hybrid), ZNF528 (Affinity Capture-RNA), ZNF528 (Affinity Capture-RNA)

ESM2 similar proteins: A0JNB1, A1YF12, A1YG88, A2T759, A3KN32, B2RUI1, O43296, O75123, P10072, P17020, P17097, P51814, P52736, P52740, Q07230, Q08ER8, Q13398, Q14590, Q32KN0, Q3KQV3, Q3MIS6, Q4V8A8, Q5CZA5, Q5RBQ3, Q5RBX0, Q5RCD9, Q5RCX4, Q6GQR8, Q6NX45, Q6P9A3, Q6PK81, Q7TSH9, Q7TSI0, Q7Z7L9, Q86UD4, Q8BFS8, Q8BLB0, Q8IVP9, Q8IZ26, Q8N9F8

Diamond homologs: A0A1W2PQL4, A6NK75, A6NN14, A6NNF4, A6NP11, A8MQ14, A8MTY0, A8MUV8, A8MXY4, B4DX44, B4DXR9, E9PYI1, O14628, O43345, O75290, O75346, O75373, O75437, O95780, P0CB33, P0DKX0, P0DPD5, P16373, P17019, P17038, P21506, P35789, P52736, P52738, P52744, Q03923, Q03924, Q03936, Q03938, Q05481, Q14586, Q14593, Q14929, Q15928, Q3KNS6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

129 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	109
Likely benign	9
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1041 predictions. Top by Δscore:

Variant	Effect	Δscore
19:52405901:TTTCA:T	acceptor_loss	1.0000
19:52405902:TTCA:T	acceptor_loss	1.0000
19:52405903:TCAG:T	acceptor_loss	1.0000
19:52405904:CAG:C	acceptor_loss	1.0000
19:52405905:A:AG	acceptor_gain	1.0000
19:52405905:A:AT	acceptor_loss	1.0000
19:52405905:AG:A	acceptor_gain	1.0000
19:52405906:G:GG	acceptor_gain	1.0000
19:52405906:GG:G	acceptor_gain	1.0000
19:52405994:G:GT	donor_gain	1.0000
19:52405994:G:T	donor_gain	1.0000
19:52404202:G:GG	donor_gain	0.9900
19:52405905:AGG:A	acceptor_gain	0.9900
19:52405906:GGG:G	acceptor_gain	0.9900
19:52405906:GGGA:G	acceptor_gain	0.9900
19:52405906:GGGAC:G	acceptor_gain	0.9900
19:52405949:G:GT	donor_gain	0.9900
19:52406032:GG:G	donor_gain	0.9900
19:52406033:GG:G	donor_gain	0.9900
19:52406039:GA:G	donor_gain	0.9900
19:52406514:GGA:G	acceptor_gain	0.9900
19:52406618:G:GT	donor_gain	0.9900
19:52404391:C:G	donor_gain	0.9800
19:52405981:G:GT	donor_gain	0.9800
19:52405992:GGGAC:G	donor_gain	0.9800
19:52405993:GGACG:G	donor_gain	0.9800
19:52406033:GGTGA:G	donor_loss	0.9800
19:52406034:GTG:G	donor_loss	0.9800
19:52406035:T:A	donor_loss	0.9800
19:52406036:G:GC	donor_loss	0.9800

AlphaMissense

4204 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:52415936:T:C	F362L	0.995
19:52415938:T:A	F362L	0.995
19:52415938:T:G	F362L	0.995
19:52415768:T:C	F306L	0.994
19:52415770:C:A	F306L	0.994
19:52415770:C:G	F306L	0.994
19:52415684:T:C	F278L	0.993
19:52415686:T:A	F278L	0.993
19:52415686:T:G	F278L	0.993
19:52416356:T:C	F502L	0.993
19:52416358:C:A	F502L	0.993
19:52416358:C:G	F502L	0.993
19:52416440:T:C	F530L	0.993
19:52416442:T:A	F530L	0.993
19:52416442:T:G	F530L	0.993
19:52415600:T:C	F250L	0.992
19:52415602:C:A	F250L	0.992
19:52415602:C:G	F250L	0.992
19:52415787:T:C	L312P	0.992
19:52415852:T:C	F334L	0.992
19:52415854:T:A	F334L	0.992
19:52415854:T:G	F334L	0.992
19:52415799:A:C	Q316P	0.991
19:52405940:T:C	F17L	0.990
19:52405942:C:A	F17L	0.990
19:52405942:C:G	F17L	0.990
19:52416020:T:C	F390L	0.990
19:52416022:T:A	F390L	0.990
19:52416022:T:G	F390L	0.990
19:52415619:T:C	L256P	0.989

dbSNP variants (sampled 300 via entrez): RS1000048331 (19:52407435 C>G,T), RS1000066948 (19:52400397 C>G,T), RS1000137941 (19:52397623 A>G), RS1000230105 (19:52413160 C>A,T), RS1000240560 (19:52418359 T>C,G), RS1000631745 (19:52414024 C>A,T), RS1000832615 (19:52403310 A>G), RS1000882355 (19:52397389 C>A), RS1000936129 (19:52407107 G>A), RS1000957788 (19:52408840 T>C), RS1000988520 (19:52417455 A>G), RS1001189726 (19:52418469 C>G), RS1001203741 (19:52413864 A>G), RS1001282834 (19:52412720 G>C,T), RS1001620677 (19:52407725 G>A)

Disease associations

OMIM: gene MIM:615580 | disease phenotypes: MIM:190300

GenCC curated gene-disease

Mondo (1): essential tremor (MONDO:0003233)

Orphanet (1): NON RARE IN EUROPE: Hereditary essential tremor (Orphanet:862)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D020329	Essential Tremor	C10.228.662.350

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects expression, increases abundance, increases expression	3
bisphenol A	affects cotreatment, decreases methylation, decreases expression	2
sodium arsenite	decreases expression, increases expression	2
Particulate Matter	increases abundance, increases expression	2
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
potassium chromate(VI)	increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Doxorubicin	decreases expression	1
Folic Acid	decreases expression	1
Ozone	affects expression, increases abundance	1
Vanadates	decreases expression	1
Aflatoxin B1	decreases expression	1

Clinical trials (associated diseases)

235 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00439699	PHASE4	COMPLETED	A Pilot Clinical Trial Of Memantine for Essential Tremor
NCT00584376	PHASE4	COMPLETED	Pregabalin (Lyrica) for the Treatment of Essential Tremor
NCT00998660	PHASE4	COMPLETED	RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)
NCT02111369	PHASE4	COMPLETED	Propranolol and Botulinum Toxin for Essential Vocal Tremor
NCT02495883	PHASE4	COMPLETED	Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response
NCT00018564	PHASE3	COMPLETED	Novel Therapies for Essential Tremor
NCT00236496	PHASE3	COMPLETED	A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
NCT01441284	PHASE3	WITHDRAWN	Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor
NCT04193527	PHASE3	COMPLETED	A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
NCT04265209	PHASE3	COMPLETED	[18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson’s Diseases and Essential Tremor
NCT06087276	PHASE3	ENROLLING_BY_INVITATION	Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)
NCT00080366	PHASE2	COMPLETED	Octanol to Treat Essential Tremor
NCT00102596	PHASE2	COMPLETED	Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00223743	PHASE2	COMPLETED	A Safety/Efficacy Trial of Zonisamide for Essential Tremor
NCT00321087	PHASE2	TERMINATED	A Study of T2000 in Essential Tremor
NCT00598078	PHASE2	COMPLETED	Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00655278	PHASE2	TERMINATED	T2000 in Essential Tremor - Open Label Continuation
NCT01332695	PHASE2	COMPLETED	A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
NCT02277106	PHASE2	COMPLETED	Evaluate SAGE-547 in Participants With Essential Tremor
NCT02551848	PHASE2	UNKNOWN	Kinematic-based BoNT-A Injections for Bilateral ET
NCT02668146	PHASE2	UNKNOWN	An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
NCT02978781	PHASE2	COMPLETED	A Study to Evaluate SAGE-217 in Participants With Essential Tremor
NCT03101241	PHASE2	COMPLETED	A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03688685	PHASE2	COMPLETED	A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03780426	PHASE2	COMPLETED	tSMS in Essential Tremor
NCT04305275	PHASE2	COMPLETED	A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04727658	PHASE2	TERMINATED	Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL)
NCT04880616	PHASE2	COMPLETED	Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
NCT05021978	PHASE2	COMPLETED	A Clinical Trial of PRAX-944 in Participants With Essential Tremor
NCT05021991	PHASE2	COMPLETED	A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
NCT05122650	PHASE2	COMPLETED	A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
NCT05173012	PHASE2	COMPLETED	Study to Evaluate SAGE-324 in Participants With Essential Tremor
NCT05387642	PHASE2	WITHDRAWN	A Clinical Trial of PRAX-114 in Participants With Essential Tremor
NCT06312800	PHASE2	WITHDRAWN	Acamprosate and Methazolamide for Essential Tremor
NCT06821906	PHASE2	RECRUITING	Stereotactic Radiosurgery in the Treatment of Essential Tremor
NCT07074002	PHASE2	RECRUITING	Proof of Concept Study on BP1.4979 Effect on Essential Tremor
NCT07103265	PHASE2	NOT_YET_RECRUITING	Developing a New LIFU Neuromodulation Method to Suppress Tremor
NCT00001986	PHASE1	COMPLETED	1-Octanol to Treat Essential Tremor
NCT00016679	PHASE1	COMPLETED	1-Octanol to Treat Essential Tremor
NCT01304758	PHASE1	COMPLETED	ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor